CAPR - Company ID 0001133869
CAPRICOR THERAPEUTICS, INC. trades as CAPR and has a market capitalization of $1.30 B, making it the #2458 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $0.00, down 100.0% from the prior year and net income of -$105.04M. This page tracks CAPRICOR THERAPEUTICS, INC. through 943 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-10
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin expanded from -470.3% to -181.7% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| 144/A | - | 2026-05-19 |
| Insider sale notice | 144 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-12 |
| Major company event | 8-K | 2026-05-07 |
| Insider trade | 4 | 2026-05-04 |
Capricor Therapeutics Expands Commercial Leadership Team
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update :: Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 :: Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting :: Capricor Therapeutics, Inc. (CAPR)
The largest companies sharing CAPRICOR THERAPEUTICS, INC.'s SEC industry classification (pharmaceutical preparations).
CAPRICOR THERAPEUTICS, INC. (CAPR) has a market capitalization of $1.30 B as of 2026-07-10, ranking #2458 among US-listed companies.
CAPRICOR THERAPEUTICS, INC. reported revenue of $0.00 for fiscal year 2025, a decrease of 100.0% year over year.
In its latest fiscal year CAPRICOR THERAPEUTICS, INC. reported a net loss of $105.04M.